Ledger.Open graph →
SEC Form D · filed February 3, 2021

Exacis Biotherapeutics Inc

Offering
$3.0M
Sold
$1.1M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
CAMBRIDGE, MA
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (9)

Mark Corrigan · Cambridge, MADirectorMatthew Angel · Cambridge, MADirectorGregory Fiore · Cambridge, MAExecLattice Capital II GP LLC · San Francisco, CADirectorAndrew A. Tisdale · Providence, RIDirectorRegan Bozman · San Francisco, CAExecMike Jacobellis · New York, NYDirectorScott Radke · New York, NYExecPhilippe Schulligen · Duluth, GADirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗